Meeting
2011 ASCO Annual Meeting
Feasibility of vincristine, dactinomycin, and cyclophosphamide (VAC) chemotherapy for adult rhabdomyosarcoma (RMS) with regard to dose intensity (DI).
Authors
Y. Kojima
National Cancer Center Hospital, Tokyo, Japan
Y. Kojima , K. Hashimoto , M. Ando , K. Yonemori , H. Yamamoto , M. Kodaira , M. Yunokawa , C. Shimizu , K. Tamura , N. Katsumata , A. Makimoto , Y. Fujiwara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Citation
J Clin Oncol 29: 2011 (suppl; abstr 10083)
Abstract #
10083
Poster Bd #
50B
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Clinical outcomes in adult and childhood rhabdomyosarcoma (RMS) treated with vincristine, dactinomycin, and cyclophosphamide (VAC)/VAC-like chemotherapy.
First Author: K. Harano
Poster
2022 ASCO Annual Meeting
Risk-adapted local therapy and intensive chemotherapy in patients with high-risk rhabdomyosarcoma.
First Author: Michael W. Bishop
Poster
2022 ASCO Annual Meeting
ARST2031: A study to compare early use of vinorelbine and maintenance therapy for patients with high risk rhabdomyosarcoma.
First Author: Wendy A Allen-Rhoades
Poster
2017 ASCO Annual Meeting
Rhabdomyosarcoma (RMS) in adults: Histologic subtypes and overall survival with actinomycin-based chemotherapy vs doxorubicin-based chemotherapy.
First Author: Alia Vang